Income Statement Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 06/03/2026 GMT			5-day change	1st Jan Change
60.29 ^USD	-0.74%		-3.33%	+11.77%

03-07	Bristol Myers Squibb Receives U.S. FDA Approval For Sotyktu For Treatment Of Adults With Active Psoriatic Arthritis	CI
03-06	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT

d4b4ee.xTOfsyu3tmclpwQWqcS6RuapNsZdhOMkArF9kb_N3dA.knDm7H_khA5t4UAh6qHgDLTtcpYasKJzcsUp39C0iKm0f9LlSvLYJELkbw

Published financial data: BRISTOL-MYERS SQUIBB COMPANY

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	46.38B	46.16B	45.01B	48.3B	48.19B
Total Revenues	46.38B	46.16B	45.01B	48.3B	48.19B
Cost of Goods Sold, Total	9.34B	9.78B	10.52B	11.95B	13.19B
Gross Profit	37.05B	36.38B	34.49B	36.35B	35B
Selling General & Admin Expenses, Total	7.67B	7.7B	7.68B	7.86B	7.15B
R&D Expenses	9.53B	9.2B	9.11B	9.78B	9.49B
Amortization of Goodwill and Intangible Assets - (IS)	10.02B	9.6B	9.05B	8.87B	3.32B
Other Operating Expenses, Total	27.23B	26.5B	25.84B	26.52B	19.96B
Operating Income	9.82B	9.88B	8.65B	9.83B	15.04B
Interest Expense, Total	-1.29B	-1.15B	-1.16B	-1.96B	-1.89B
Interest And Investment Income	39M	171M	449M	478M	586M
Net Interest Expenses	-1.25B	-982M	-712M	-1.48B	-1.31B
Income (Loss) On Equity Invest.	231M	-108M	-38M	44M	47M
Currency Exchange Gains (Loss)	21M	96M	160M	31M	92M
Other Non Operating Income (Expenses)	1.66B	1.82B	2.08B	1.48B	2.12B
EBT, Excl. Unusual Items	10.48B	10.7B	10.14B	9.91B	16B
Restructuring Charges	-187M	-144M	-535M	-867M	-789M
Merger & Related Restructuring Charges	-831M	-863M	-326M	-1.1B	-300M
Gain (Loss) On Sale Of Investments	514M	-693M	-122M	-28M	233M
Gain (Loss) On Sale Of Assets	9M	211M	-	-15M	-1M
Asset Writedown	-1.16B	-98M	-107M	-2.82B	-949M
In Process R&D Expenses	-	-815M	-913M	-13.37B	-3.72B
Legal Settlements	-82M	-178M	-10M	-84M	-434M
Other Unusual Items	-647M	-410M	313M	-	-707M
EBT, Incl. Unusual Items	8.1B	7.71B	8.44B	-8.38B	9.33B
Income Tax Expense	1.08B	1.37B	400M	554M	2.27B
Earnings From Continuing Operations	7.01B	6.34B	8.04B	-8.93B	7.06B
Net Income to Company	7.01B	6.34B	8.04B	-8.93B	7.06B
Minority Interest	-20M	-18M	-15M	-15M	-2M
Net Income - (IS)	6.99B	6.33B	8.02B	-8.95B	7.05B
Net Income to Common Incl Extra Items	6.99B	6.33B	8.02B	-8.95B	7.05B
Net Income to Common Excl. Extra Items	6.99B	6.33B	8.02B	-8.95B	7.05B
Per Share Items
Net EPS - Basic	3.15	2.97	3.88	-4.41	3.47
Basic EPS - Continuing Operations	3.15	2.97	3.88	-4.41	3.47
Basic Weighted Average Shares Outstanding	2.22B	2.13B	2.07B	2.03B	2.03B
Net EPS - Diluted	3.12	2.95	3.86	-4.41	3.46
Diluted EPS - Continuing Operations	3.12	2.95	3.86	-4.41	3.46
Diluted Weighted Average Shares Outstanding	2.24B	2.15B	2.08B	2.03B	2.04B
Normalized Basic EPS	2.94	3.13	3.06	3.05	4.91
Normalized Diluted EPS	2.91	3.11	3.04	3.05	4.9
Dividend Per Share	2.01	2.19	2.31	2.42	2.49
Payout Ratio	62.85	73.24	59.12	-54.35	71.52
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	20.58B	20.16B	18.42B	19.41B	19.12B
EBITA	20.02B	19.58B	17.85B	18.83B	18.54B
EBIT	9.82B	9.88B	8.65B	9.83B	15.04B
EBITDAR	20.85B	20.45B	18.82B	19.76B	19.46B
Total Revenues (As Reported)	46.38B	46.16B	45.01B	48.3B	48.19B
Effective Tax Rate - (Ratio)	13.39	17.74	4.74	-6.61	24.36
Current Domestic Taxes	1.88B	3.02B	2.74B	1.28B	1.7B
Current Foreign Taxes	598M	1.09B	943M	1.36B	1.54B
Total Current Taxes	2.48B	4.11B	3.69B	2.64B	3.24B
Deferred Domestic Taxes	-1.26B	-2.89B	-2.34B	-2.18B	-1.11B
Deferred Foreign Taxes	-138M	151M	-949M	96M	142M
Total Deferred Taxes	-1.39B	-2.74B	-3.29B	-2.09B	-965M
Normalized Net Income	6.53B	6.67B	6.32B	6.18B	10B
Interest Capitalized	-	-	-	-	-
Non-Cash Pension Expense	-23M	27M	11M	15M	28M
Supplemental Operating Expense Items
Advertising Expense	1.3B	1.3B	1.4B	1.5B	-
Selling and Marketing Expenses	1.3B	1.3B	1.4B	1.5B	-
Research And Development Expense From Footnotes	11.35B	10.32B	10.21B	24.53B	13.67B
Net Rental Expense, Total	274M	293M	405M	352M	341M
Imputed Operating Lease Interest Expense	58.22M	62.55M	91.36M	119M	105M
Imputed Operating Lease Depreciation	216M	230M	314M	233M	236M
Stock-Based Comp., COGS (Total)	57M	41M	51M	57M	62M
Stock-Based Comp., R&D Exp. (Total)	272M	221M	252M	248M	267M
Stock-Based Comp., SG&A Exp. (Total)	241M	195M	215M	202M	224M
Stock-Based Comp., Other (Total)	13M	-	-	-	-
Total Stock-Based Compensation	583M	457M	518M	507M	553M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	13.98B	9.12B	11.46B	10.35B	10.21B
Short Term Investments	3.24B	130M	816M	513M	464M
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	17.22B	9.25B	12.28B	10.86B	10.67B
Accounts Receivable, Total	9.73B	10.39B	11.34B	11.13B	11.61B
Other Receivables	2.79B	3.55B	3.93B	3.29B	2.92B
Total Receivables	12.52B	13.94B	15.26B	14.42B	14.53B
Inventory	2.1B	2.34B	2.66B	2.56B	2.69B
Prepaid Expenses	-	-	-	-	-
Restricted Cash	140M	148M	55M	-	-
Other Current Assets, Total	1.29B	1.6B	1.51B	1.94B	1.5B
Total Current Assets	33.26B	27.27B	31.77B	29.78B	29.39B
Gross Property Plant And Equipment	11B	11.64B	12.84B	13.31B	14.42B
Accumulated Depreciation	-4.03B	-4.16B	-4.8B	-4.95B	-5.29B
Net Property Plant And Equipment	6.97B	7.48B	8.04B	8.36B	9.12B
Long-term Investments	2.71B	2.19B	2.06B	2.06B	2.49B
Goodwill	20.5B	21.15B	21.17B	21.72B	21.75B
Other Intangibles, Total	42.53B	35.86B	27.07B	23.31B	19.1B
Accounts Receivable Long-Term	-	-	-	-	-
Deferred Tax Assets Long-Term	1.44B	1.34B	2.77B	4.24B	5.38B
Deferred Charges Long-Term	248M	496M	413M	336M	250M
Other Long-Term Assets, Total	1.66B	1.04B	1.87B	2.81B	2.55B
Total Assets	109B	96.82B	95.16B	92.6B	90.04B
Liabilities
Accounts Payable, Total	2.95B	3.04B	3.26B	3.6B	3.58B
Accrued Expenses, Total	9.94B	10.24B	11.04B	13.13B	12.86B
Short-term Borrowings	184M	367M	246M	218M	284M
Current Portion of Long-Term Debt	4.76B	3.9B	2.87B	1.83B	1.98B
Current Portion of Leases	169M	136M	162M	181M	202M
Current Income Taxes Payable	754M	942M	1.37B	1.51B	979M
Unearned Revenue Current, Total	-	-	-	-	-
Other Current Liabilities	3.11B	3.27B	3.31B	3.3B	3.54B
Total Current Liabilities	21.87B	21.89B	22.26B	23.77B	23.42B
Long-Term Debt	39.6B	35.16B	36.71B	47.64B	42.9B
Long-Term Leases	874M	1.26B	1.53B	1.37B	1.83B
Unearned Revenue Non Current	326M	283M	300M	230M	169M
Pension & Other Post Retirement Benefits	654M	402M	480M	400M	330M
Deferred Tax Liability Non Current	4.5B	2.17B	338M	369M	222M
Other Non Current Liabilities	5.48B	4.54B	4.05B	2.43B	2.67B
Total Liabilities	73.31B	65.7B	65.67B	76.22B	71.53B
Common Stock, Total	292M	292M	292M	292M	292M
Additional Paid In Capital	44.36B	45.16B	45.68B	46.02B	46.39B
Retained Earnings	23.82B	25.5B	28.77B	14.91B	16.9B
Treasury Stock	-31.26B	-38.62B	-43.77B	-43.66B	-43.58B
Comprehensive Income and Other	-1.27B	-1.28B	-1.55B	-1.24B	-1.52B
Total Common Equity	35.95B	31.06B	29.43B	16.34B	18.47B
Minority Interest	60M	57M	55M	53M	33M
Total Equity	36.01B	31.12B	29.48B	16.39B	18.51B
Total Liabilities And Equity	109B	96.82B	95.16B	92.6B	90.04B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.18B	2.1B	2.02B	2.03B	2.04B
ECS Total Common Shares Outstanding	2.18B	2.1B	2.02B	2.03B	2.04B
Book Value / Share	16.52	14.81	14.56	8.05	9.07
Tangible Book Value	-27.08B	-25.95B	-18.81B	-28.69B	-22.38B
Tangible Book Value Per Share	-12.45	-12.37	-9.31	-14.14	-10.99
Total Debt	45.6B	40.82B	41.52B	51.24B	47.19B
Net Debt	28.38B	31.57B	28.88B	40.06B	36.12B
Debt Equivalent of Unfunded Proj. Benefit Obligation	120M	-51M	26M	18M	-100M
Debt Equivalent Oper. Leases	2.19B	2.34B	3.24B	2.82B	2.73B
Minority Interest, Total (Incl. Fin. Div)	60M	57M	55M	53M	33M
Equity Method Investments, Total	666M	546M	542M	598M	738M
Account Code - Inventory Valuation	6	6	6	6	6
Land - (BS)	169M	162M	162M	161M	157M
Buildings, Total	5.9B	5.92B	6.5B	6.58B	7.27B
Machinery, Total	3.25B	3.28B	3.72B	3.82B	3.79B
Full Time Employees	32.2K	34.3K	34.1K	34.1K	32.5K
Accumulated Allowance for Doubtful Accounts (Supple)	21M	22M	23M	45M	58M

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	6.99B	6.33B	8.02B	-8.95B	7.05B
Depreciation & Amortization - CF	557M	582M	569M	575M	577M
Amortization of Goodwill and Intangible Assets - (CF)	10.2B	9.7B	9.2B	9B	3.5B
Depreciation & Amortization, Total	10.76B	10.28B	9.77B	9.58B	4.08B
(Gain) Loss From Sale Of Asset	-684M	-231M	-22M	-15M	-36M
(Gain) Loss on Sale of Investments - (CF)	-745M	801M	160M	-16M	-280M
Asset Writedown & Restructuring Costs	1.21B	184M	1.21B	16.41B	4.86B
Stock-Based Compensation (CF)	583M	457M	518M	507M	553M
Other Operating Activities, Total	-654M	-2.52B	-3.89B	-3.14B	-1.62B
Change In Accounts Receivable	-1.05B	-663M	-995M	264M	-295M
Change In Inventories	13M	-69M	-751M	-486M	-184M
Change In Accounts Payable	245M	109M	198M	184M	-2M
Change in Unearned Revenues	-	-	-	-	-
Change In Income Taxes	-1.06B	-1.42B	-603M	-1.26B	-4M
Change in Other Net Operating Assets	606M	-183M	237M	2.11B	30M
Cash from Operations	16.21B	13.07B	13.86B	15.19B	14.16B
Capital Expenditure	-973M	-1.12B	-1.21B	-1.25B	-1.31B
Cash Acquisitions	-1.61B	-4.29B	-1.17B	-21.82B	-3.94B
Divestitures	748M	1.3B	909M	1.1B	1.07B
Investment in Marketable and Equity Securities, Total	1.3B	3.04B	-826M	618M	52M
Cash from Investing	-538M	-1.06B	-2.3B	-21.35B	-4.13B
Short Term Debt Issued, Total	-	194M	-	3.09B	25M
Long-Term Debt Issued, Total	-	5.93B	4.46B	12.88B	5.74B
Total Debt Issued	-	6.12B	4.46B	15.97B	5.76B
Short Term Debt Repaid, Total	-160M	-	-120M	-3B	-
Long-Term Debt Repaid, Total	-6.02B	-11.43B	-3.88B	-2.87B	-10.94B
Total Debt Repaid	-6.18B	-11.43B	-4B	-5.87B	-10.94B
Issuance of Common Stock	-	-	-	-	-
Repurchase of Common Stock	-6.29B	-8B	-5.16B	-	-
Common Dividends Paid	-4.4B	-4.63B	-4.74B	-4.86B	-5.04B
Common & Preferred Stock Dividends Paid	-4.4B	-4.63B	-4.74B	-4.86B	-5.04B
Other Financing Activities, Total	641M	984M	27M	-106M	-128M
Cash from Financing	-16.22B	-16.96B	-9.42B	5.13B	-10.35B
Foreign Exchange Rate Adjustments	-102M	-33M	45M	-137M	195M
Net Change in Cash	-657M	-4.99B	2.19B	-1.17B	-129M
Supplemental Items
Cash Interest Paid	1.5B	1.4B	1.2B	1.8B	2.1B
Cash Income Tax Paid (Refund)	3.5B	5.4B	4.3B	3.9B	3.26B
Levered Free Cash Flow	13.57B	13.83B	13.78B	16.89B	11.15B
Unlevered Free Cash Flow	14.38B	14.56B	14.51B	18.11B	12.33B
Change In Net Working Capital	2.12B	1.24B	-21M	-3.14B	389M
Net Debt Issued / Repaid	-6.18B	-5.31B	456M	10.1B	-5.18B

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	5.39	5.99	5.63	6.55	10.29
Return on Total Capital	7.17	8.04	7.56	8.87	14.1
Return On Equity %	18.99	18.91	26.53	-38.95	40.44
Return on Common Equity	18.96	18.88	26.53	-39.1	40.53
Margin Analysis
Gross Profit Margin %	79.87	78.81	76.63	75.26	72.62
SG&A Margin	16.54	16.69	17.06	16.28	14.84
EBITDA Margin %	44.37	43.68	40.93	40.18	39.66
EBITA Margin %	43.16	42.42	39.66	38.99	38.47
EBIT Margin %	21.17	21.4	19.22	20.36	31.21
Income From Continuing Operations Margin %	15.12	13.75	17.86	-18.49	14.64
Net Income Margin %	15.08	13.71	17.83	-18.53	14.64
Net Avail. For Common Margin %	15.08	13.71	17.83	-18.53	14.64
Normalized Net Income Margin	14.07	14.45	14.05	12.79	20.74
Levered Free Cash Flow Margin	29.26	29.97	30.62	34.97	23.13
Unlevered Free Cash Flow Margin	31.01	31.53	32.23	37.5	25.58
Asset Turnover
Asset Turnover	0.41	0.45	0.47	0.51	0.53
Fixed Assets Turnover	6.77	6.39	5.8	5.89	5.51
Receivables Turnover (Average Receivables)	5.02	4.59	4.14	4.3	4.24
Inventory Turnover (Average Inventory)	4.48	4.41	4.21	4.58	5.03
Short Term Liquidity
Current Ratio	1.52	1.25	1.43	1.25	1.26
Quick Ratio	1.36	1.06	1.24	1.06	1.08
Operating Cash Flow to Current Liabilities	0.74	0.6	0.62	0.64	0.6
Days Sales Outstanding (Average Receivables)	72.73	79.55	88.1	85.13	86.1
Days Outstanding Inventory (Average Inventory)	81.49	82.73	86.77	79.93	72.58
Average Days Payable Outstanding	110.42	109.03	106.04	106.01	98.28
Cash Conversion Cycle (Average Days)	43.79	53.25	68.84	59.05	60.4
Long Term Solvency
Total Debt/Equity	126.63	131.18	140.82	312.65	254.98
Total Debt / Total Capital	55.88	56.74	58.48	75.77	71.83
LT Debt/Equity	112.42	117.04	129.69	299.06	241.67
Long-Term Debt / Total Capital	49.61	50.63	53.85	72.47	68.08
Total Liabilities / Total Assets	67.06	67.86	69.02	82.3	79.45
EBIT / Interest Expense	7.6	8.57	7.45	5.02	7.95
EBITDA / Interest Expense	16.14	17.74	16.21	10.09	10.28
(EBITDA - Capex) / Interest Expense	15.39	16.77	15.17	9.45	9.59
Total Debt / EBITDA	2.19	2	2.21	2.59	2.43
Net Debt / EBITDA	1.36	1.54	1.53	2.03	1.86
Total Debt / (EBITDA - Capex)	2.29	2.11	2.36	2.77	2.6
Net Debt / (EBITDA - Capex)	1.43	1.63	1.64	2.16	1.99
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	9.09	-0.49	-2.5	7.32	-0.22
Gross Profit, 1 Yr. Growth %	8.82	-1.81	-5.2	5.4	-3.72
EBITDA, 1 Yr. Growth %	13.17	-2.97	-8.64	5.36	-1.5
EBITA, 1 Yr. Growth %	13.43	-3.18	-8.83	5.5	-1.56
EBIT, 1 Yr. Growth %	26.72	-1.42	-12.43	13.65	52.96
Earnings From Cont. Operations, 1 Yr. Growth %	-177.98	-9.54	26.71	-211.11	-178.99
Net Income, 1 Yr. Growth %	-177.58	-9.54	26.84	-211.5	-178.83
Normalized Net Income, 1 Yr. Growth %	29.9	-0.2	-5.23	-2.68	61.8
Diluted EPS Before Extra, 1 Yr. Growth %	-178.15	-5.45	30.85	-214.36	-178.38
Accounts Receivable, 1 Yr. Growth %	11.14	6.78	9.11	-1.81	4.26
Inventory, 1 Yr. Growth %	1.01	11.65	13.81	-3.94	5.2
Net Property, Plant and Equip., 1 Yr. Growth %	3.31	7.28	7.5	4.03	9.15
Total Assets, 1 Yr. Growth %	-7.74	-11.43	-1.72	-2.69	-2.77
Tangible Book Value, 1 Yr. Growth %	-24.7	-4.19	-27.5	52.52	-21.98
Common Equity, 1 Yr. Growth %	-4.96	-13.59	-5.25	-44.5	13.09
Cash From Operations, 1 Yr. Growth %	15.34	-19.38	6.08	9.6	-6.81
Capital Expenditures, 1 Yr. Growth %	29.22	14.9	8.14	3.23	5.05
Levered Free Cash Flow, 1 Yr. Growth %	-17.28	0.99	-0.16	22.57	-34
Unlevered Free Cash Flow, 1 Yr. Growth %	-16.74	0.34	-0.34	24.87	-31.93
Dividend Per Share, 1 Yr. Growth %	9.24	8.96	5.48	4.76	2.89
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	33.2	4.19	-1.5	2.29	3.48
Gross Profit, 2 Yr. CAGR %	42.49	8.78	-2.72	0.46	0.9
EBITDA, 2 Yr. CAGR %	62.45	20.76	-2.38	-0.04	2.67
EBITA, 2 Yr. CAGR %	64.75	21.37	-2.48	-0.02	2.74
EBIT, 2 Yr. CAGR %	27.13	70.68	0.46	3.71	34.08
Earnings From Cont. Operations, 2 Yr. CAGR %	42.38	-16.01	7.06	18.65	-6.32
Net Income, 2 Yr. CAGR %	42.61	-16.22	7.12	18.92	-6.24
Normalized Net Income, 2 Yr. CAGR %	21.4	69.35	4.59	-0.31	27.29
Diluted EPS Before Extra, 2 Yr. CAGR %	24.59	-14.04	11.23	22.33	-5.32
Accounts Receivable, 2 Yr. CAGR %	12.52	8.94	7.94	3.51	1.18
Inventory, 2 Yr. CAGR %	-30.14	6.2	12.72	4.56	0.52
Net Property, Plant and Equip., 2 Yr. CAGR %	0.09	5.27	7.39	5.75	6.56
Total Assets, 2 Yr. CAGR %	-8.28	-9.6	-6.7	-2.2	-2.73
Tangible Book Value, 2 Yr. CAGR %	-11.86	-15.07	-16.66	5.15	9.08
Common Equity, 2 Yr. CAGR %	-16.53	-9.38	-9.52	-27.48	-20.77
Cash From Operations, 2 Yr. CAGR %	40.5	-3.57	-7.52	7.82	1.06
Capital Expenditures, 2 Yr. CAGR %	7.88	21.85	11.47	5.65	4.13
Levered Free Cash Flow, 2 Yr. CAGR %	58.07	0.54	3.81	12.52	-9.47
Unlevered Free Cash Flow, 2 Yr. CAGR %	54.9	0.02	3.27	13.37	-7.23
Dividend Per Share, 2 Yr. CAGR %	9.38	9.1	7.2	5.12	3.82
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	27.16	20.86	1.91	1.36	1.45
Gross Profit, 3 Yr. CAGR %	31.88	25.86	3.9	-0.09	-0.95
EBITDA, 3 Yr. CAGR %	51.93	37.25	10.04	0.13	-0.53
EBITA, 3 Yr. CAGR %	54.06	38.45	10.33	0.11	-0.54
EBIT, 3 Yr. CAGR %	23	17.58	36.64	4.68	18.05
Earnings From Cont. Operations, 3 Yr. CAGR %	12.34	22.4	-3.67	8.4	3.6
Net Income, 3 Yr. CAGR %	12.44	22.53	-3.8	8.56	3.69
Normalized Net Income, 3 Yr. CAGR %	16.69	14.63	39.55	2.25	17.16
Diluted EPS Before Extra, 3 Yr. CAGR %	1.2	13.64	-1.12	12.26	5.46
Accounts Receivable, 3 Yr. CAGR %	19.19	10.58	9	4.59	3.76
Inventory, 3 Yr. CAGR %	20.58	-18.32	8.68	6.87	4.77
Net Property, Plant and Equip., 3 Yr. CAGR %	11.5	2.43	6.01	6.26	6.87
Total Assets, 3 Yr. CAGR %	46.19	-9.34	-7.05	-5.38	-2.39
Tangible Book Value, 3 Yr. CAGR %	61.73	-9.37	-19.43	1.94	-4.8
Common Equity, 3 Yr. CAGR %	36.83	-15.56	-8.02	-23.12	-15.9
Cash From Operations, 3 Yr. CAGR %	31.88	16.75	-0.46	-2.14	2.71
Capital Expenditures, 3 Yr. CAGR %	0.77	10.17	17.1	8.65	5.45
Levered Free Cash Flow, 3 Yr. CAGR %	75.21	36.56	0.23	9.72	-5.81
Unlevered Free Cash Flow, 3 Yr. CAGR %	76.43	34.41	-0.1	10.02	-4.36
Dividend Per Share, 3 Yr. CAGR %	7.68	9.24	7.88	6.38	4.37
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	19.01	17.31	14.81	13.06	2.54
Gross Profit, 5 Yr. CAGR %	20.67	19.53	16.38	14.78	2.63
EBITDA, 5 Yr. CAGR %	29.23	34.6	25.71	20	6.7
EBITA, 5 Yr. CAGR %	30.13	36.25	26.66	20.62	6.88
EBIT, 5 Yr. CAGR %	13.62	19.94	10.39	10.1	34.7
Earnings From Cont. Operations, 5 Yr. CAGR %	9.25	45.44	10.2	20.89	-4.74
Net Income, 5 Yr. CAGR %	9.43	44.42	10.28	21.08	-4.79
Normalized Net Income, 5 Yr. CAGR %	11.23	14.45	9	6.88	33.85
Diluted EPS Before Extra, 5 Yr. CAGR %	3.32	37.06	5.1	17.04	-2.82
Accounts Receivable, 5 Yr. CAGR %	14.63	13.12	14.55	7.69	5.8
Inventory, 5 Yr. CAGR %	11.04	14.94	17.37	-9.84	5.34
Net Property, Plant and Equip., 5 Yr. CAGR %	6.95	8.37	9.84	3.75	6.23
Total Assets, 5 Yr. CAGR %	26.53	23.61	22.16	-6.55	-5.34
Tangible Book Value, 5 Yr. CAGR %	27.89	47.89	24.06	-3.82	-9.05
Common Equity, 5 Yr. CAGR %	17.31	21.48	15.97	-20.55	-13.35
Cash From Operations, 5 Yr. CAGR %	39.59	19.89	14.42	13.09	0.15
Capital Expenditures, 5 Yr. CAGR %	-4.35	1.17	4.92	8.34	11.73
Levered Free Cash Flow, 5 Yr. CAGR %	57.26	45.37	40.42	25.46	-4.02
Unlevered Free Cash Flow, 5 Yr. CAGR %	56.83	45.22	40.83	24.75	-3.26
Dividend Per Share, 5 Yr. CAGR %	5.61	6.88	7.49	7.57	6.24